STI Vaccine and Diagnostic R&D Funding by NIH IC and Topic

This chart shows STI vaccine and diagnostic R&D funding by NIH institutes and centers and by topic.

Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.

STI Vaccine and Diagnostic R&D Funding by NIH IC

This pie chart provides a breakdown research & development funding for STI vaccines and diagnostics by NIH institutes and centers.

Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.

STI Vaccine and Diagnostic R&D Funding by Pathogen

This table shows STI vaccine and diagnostic research & development funding by pathogen.

Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.

STI Vaccine and Diagnostic R&D Funding by Topic

This pie chart shows research & development funding for STI vaccines and diagnostics by topic.

Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.

STI Vaccine and Diagnostic R&D Funding by Sector

This pie chart shows research & development funding for STI vaccines and diagnostics by sector — public and philanthropic.

Excerpted from STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments, the full report is available at stiwatch.org/resource-tracking.

STIs: A Review of the 2022 Vaccine and Diagnostic R&D Pipeline and Investments 

This report examines disbursements by the U.S. NIH and the Bill & Melinda Gates Foundation and is one of few reports to track funding trends in vaccine and diagnostics R&D, and pipeline investments for some of the most common STIs, including chlamydia, genital herpes, gonorrhea, hepatitis B, human papillomavirus (HPV), syphilis, and trichomoniasis.

AVAC in Conversation with NIAID’s Jeanne Marrazzo

The new director of National Institute of Allergy and Infectious Diseases (NIAID), Dr. Jeanne Marrazzo joined AVAC Executive Director in conversation.

Recording

CAB for PrEP for Advocates

Basics of Injectable Cabotegravir for HIV Prevention

This wide-ranging presentation introduces advocates to cabotegravir injectable PrEP. The slides provide a background on clinical research, what users think, regulatory status and prepares advocates for implementation.

Coalition to Accelerate Access to Long-Acting PrEP

The Coalition to Accelerate Access to Long-Acting PrEP is an initiative that brings together leading donors, agencies, and advocates to ensure an accelerated, equitable, sustainable and collaborative approach to making longer-acting PrEP options accessible as quickly and as equitably as possible. The Coalition is convened by Unitaid, WHO, UNAIDS, Global Fund and PEPFAR, with AVAC as the Secretariat.

Coalition to Accelerate Access to Long-Acting PrEP

The Coalition to Accelerate Access to Long-Acting PrEP brings together leading donors, agencies, and advocates aimed at a practical goal: jointly develop strategies and take coordinated action to identify and overcome access challenges to just-approved and future PrEP options. AVAC serves as the Secretariat.

Find more information here.